| Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. | |
| | |
MedLine Citation:
|
PMID: 21048536 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this prospective, randomized, double-blinded, placebo-controlled single center study was to evaluate an early steroid-free immunosuppression in liver transplant patients. METHODS: From March 2000 to October 2004, 110 patients were included. All patients received tacrolimus and steroids during the first 2 weeks after orthotopic liver transplantation (OLT). Thereafter, patients in the steroid group (n=54) received steroids and the remaining 56 a placebo. After 6 months, the immunosuppression for all was steroid free. Thirty patients were hepatitis C positive. Five years after inclusion, patient survival, organ survival, steroid side effects, and recirrhosis in hepatitis C virus (HCV) patients were reevaluated. RESULTS: After 5 years, the following parameters were comparable in both groups: patient survival (P=0.236), organ survival (P=0.509), and acute rejections (P=0.409). Steroid-free immunosuppression lead to a higher rate of chronic rejections (P=0.023). Six months after OLT, there was a difference in rates of posttransplant diabetes mellitus (PTDM) (P=0.024) and hypercholesterolemia (P=0.002). However, 5 years after OLT, there was no difference in hypertension (P=0.647), PTDM (P=0.453), hypercholesterolemia (P=0.412), and osteoporosis (P=0.624). In HCV patients, we could not find any differences in patient survival (P=0.096), organ survival (P=0.424), time free from recirrhosis (P=0.647). The rate of recirrhosis was influenced by steroid bolus therapy (P=0.01) but not by avoiding continuous steroid therapy. CONCLUSIONS: Early tapering down of steroids to a tacrolimus monotherapy is possible with comparable acute rejection rates. During steroid therapy, PTDM and hypercholesterolemia are cumulative. These side effects are reversible. The recirrhosis in HCV patients is not influenced by continuous steroid therapy but more frequent in HCV patients receiving a steroid bolus therapy. |
| | |
Authors:
|
Nina Weiler; Ina Thrun; Maria Hoppe-Lotichius; Tim Zimmermann; Irene Kraemer; Gerd Otto |
Related Documents
:
|
23050706 - Hallux valgus correction using transarticular lateral release with distal chevron osteo... 23386766 - Relationship between glycosylated hemoglobin level and sciatic nerve block performance ... 23514646 - Risk factors for intraocular pressure rise following phacoemulsification. 2298966 - Treatment of severe lichen planus with cyclosporine. 8403676 - A comparison of gentamicin-impregnated polymethylmethacrylate bead implantation to conv... 18472696 - Long term follow up of hiv-infected patients with tuberculosis treated with 6-month int... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Transplantation Volume: 90 ISSN: 1534-6080 ISO Abbreviation: Transplantation Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-16 Completed Date: 2011-01-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0132144 Medline TA: Transplantation Country: United States |
Other Details:
|
Languages: eng Pagination: 1562-6 Citation Subset: IM |
Affiliation:
|
Department of Transplantation and Hepatobiliarypancreatic Surgery, Hospital of Johannes Gutenberg University Mainz, Mainz, Germany. nina.weiler@unimedizin-mainz.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
administration & dosage,
therapeutic use* Diabetes Mellitus / epidemiology, etiology Dose-Response Relationship, Drug Double-Blind Method Graft Survival / drug effects Hepatitis C / surgery Humans Hypercholesterolemia / epidemiology, etiology Immunosuppressive Agents / therapeutic use Liver Cirrhosis / surgery* Liver Transplantation / immunology*, mortality Postoperative Complications / classification, epidemiology Recurrence Survival Rate Tacrolimus / therapeutic use* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Immunosuppressive Agents; 109581-93-3/Tacrolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The indirect alloimmune response causes microvascular endothelial dysfunction-a possible role for al...
Next Document: Priority setting in health research in Cuba, 2010.